

Research Article



The Levels of Prostate Specific Antigen and Leptin Hormone in Patients with Prostate Cancer

NESREEN AHMED NASSER¹, ANAS H. SADEK², BAYADIR ABDULHUSSEIN MAHMEED³, OSAMA AKRAM MOHSEIN^{4,5*}

¹Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq; ²Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq; ³Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq; ⁴Main Laboratory Unit, Thi-Qar Health Directorate, Al Habbobi Teaching Hospital, Thi-Qar, Iraq; ⁵Department of Medical Laboratory Techniques, Mazaya University College, Thi-Qar, Iraq.

Abstract | Background; Prostate cancer ranks as the sixth most commonly diagnosed cancer and is the most commonly diagnosed cancer among males worldwide. Surveillance PSA testing remains a controversial topic, although MRI scans, prostate tissue biopsies, and prostate-specific antigen (PSA) testing are the main diagnostic methods. Aims of the study: Estimating the levels of prostate cancer antigen and leptin in patients with prostate cancer and their role in the development of the disease. Methodology; The study included 35 men suffering from prostate cancer and 35 healthy men as a control group. Samples were collected at Al-Kadhimiya Hospital for the period between 1/11/2023 and 1/3/2024, and 5 ml was withdrawn from each participant and placed in a gel tube. prostate-specific antigen (PSA) and leptin levels were examined using enzyme-linked immunosorbent assays. Result; The results showed that there was no statistical significance in age or body mass index. The results also showed an increase in blood sugar, leptin, PSA, cholesterol, triglycerides, GOT, GPT, urea, and creatinine in the patient group compared to the control group. Conclusions; The increase in all biomarkers in patients with prostate cancer suggests the importance of intensifying studies on this type of cancer because of its future risks.

Keywords: Prostate cancer, Leptin, Liver function test, Renal function test, Lipid profile, Prostate-Specific Antigen.

Received | June 12, 2024 Accepted | July 04, 2024; Published | August 10, 2024

*Correspondence | Osama Akram Mohsein, Department of Medical Laboratory Techniques, Mazaya University College, Thi-Qar, Iraq; Email: osamaakram889@gmail.com

Citation: Nasser NA, Sadek AH, Mahmeed BA, Mohsein OA (2024). The levels of prostate specific antigen and leptin hormone in patients with prostate cancer. S. Asian J. Life Sci. 12: 74-80.

DOI | <http://dx.doi.org/10.17582/journal.sajls/2024/12.74.80>

ISSN | 2311-0589

INTRODUCTION

Adipose tissues produce the protein hormone leptin (LEP), which primarily controls hunger and energy usage by interacting with the leptin receptor (LEPR). Leptin plays a role in the abnormal functioning of energy metabolism (Charchour et al., 2020; Garcia-Castano et al., 2019). Leptin has a crucial role in regulating various processes like reproduction, bone formation, blood cell generation, blood vessel formation, and hormone production. Additionally, it also regulates blood pressure and reproductive functions. Leptin is mainly found in adipose tissue,

although it has also been detected in the brain, muscles, and the gastrointestinal tract (Zhang et al., 2017). Insulin, cortisol, and IL-1b regulate the expression of leptin in normal physiological conditions when there is inflammation. Leptin plays a crucial role in the healing process by restoring balance and normal functioning of the body. Leptin has a substantial impact on inflammation through a wide range of metabolic effects, such as enhancing the absorption of glucose and the oxidation of fatty acids (Lateef et al., 2024). However, inflammation can often continue for a long time and might hinder the immune system's functioning, leading to disturbances in homeostasis and the

emergence of chronic pathogenic diseases such as chronic inflammation (Pérez et al., 2020). Prostate cancer (PCa) is widely reported as one of the most frequently diagnosed forms of cancer, accounting for 3.8% of cancer-related deaths worldwide and 7.1% of newly identified cases of all cancers. Prostate cancer (PCa) is associated with characteristics such as increasing age, elevated levels of androgens, being overweight or obese, and other risk factors (Brawer et al., 2003). According to reports, the use of leptin treatment has been found to enhance the growth and spread of DU145 cells while reducing cell death through the activation of ERK1/2 signalling in prostate cancer (Xu et al., 2020). The influence of leptin on the advancement of prostate cancer was examined using the DU-145 and PC3 cell lines. Leptin therapy seems to enhance the movement and transformation of cancer cells by activating the STAT3 pathway (Gorab et al., 2020). Studies on human gallbladder cancer have found that the development of the illness is greatly affected by the activation of the leptin-leptin receptor signalling pathway. Cell growth is stimulated by leptin through the activation of the leptin receptor, making this situation (Zou et al., 2016). Leptin reduced the harmful effects caused by bortezomib therapy in myeloma cells. Concurrently, there was an elevation in the levels of cyclin D1 and Bcl-2 proteins, whereas the activity of caspase 3 decreased. Leptin has been found to have a significant impact on the production and release of VEGF-C in chondrosarcoma. This, in turn, promotes the growth of lymphatic vessels in human lymphatic endothelial cells by blocking the action of miR-27b (Yang et al., 2016). A study on chondrosarcoma cells indicated the modulation of tube formation in endothelial progenitor cells through leptin-dependent mechanisms. The activation of the leptin-leptin receptor signalling pathway in cancer cells resulted in the stimulation of MAPK signalling. As a consequence, AP-1 was able to attach to the VEGF-A promoter and begin the process of transactivation (Ang et al., 2014). In addition, a correlation analysis demonstrated a substantial positive link between the concentrations of leptin and leptin receptors and the occurrence of lymph node metastases in individuals diagnosed with endometrial cancer. A study was conducted with the aim of reducing the spread of cancer through the action of leptin. Adiponectin was found to prevent the spread of SPEC-2 endometrial cancer caused by leptin by activating AMPK, which inhibits the JAK/STAT3 pathway (Zhang et al., 2014).

METHODOLOGY

The research population consisted of seventy guys, all of whom were enrolled between January 2023 and August 2023. All participants were properly informed of the purpose of our research. The participants were categorised into two groups based on their BMI and age, and each group

was assigned a specific diagnosis. The initial cohort, referred to as the PCa group, consists of 35 male patients who have received definitive confirmation of their condition. The control group, consisting of 35 healthy men, was recruited from the outpatient clinic by attending males who had the same ethnic background as the patients. Patients who were not included in our cohort were those who had acute urinary tract infections, chronic prostatitis, a previous history of urogenital malignancies, or chronic renal disease. All individuals had thorough history-taking as well as general and local clinical examinations. The study included patients who were diagnosed with prostate cancer using histology and were recruited through the urology department. Before any treatment interventions (such as surgery, hormone therapy, radiation, and others), blood samples were obtained. The BMI was calculated by dividing the weight in kilogrammes by the square of the height in metres. 10 mL of venous blood was taken into two tubes: one tube containing EDTA and one standard vacutainer tube. The two tubes were used to measure the levels of serum total PSA (TPSA) and leptin, respectively. The serum levels of leptin and tPSA were measured using an enzyme-linked immunosorbent assay (ELISA).

STATISTICAL ANALYSIS

The data was gathered using Microsoft Excel and then analysed using version 26.0 of the Statistical Package for the Social Sciences Software (SPSS, Inc., IBM Corporation). A Shapiro-Wilk test was conducted to assess the normality of the data. An analysis of variance (ANOVA) was used to investigate the variation among different groups. Subsequently, Tukey's post-hoc test was utilised to evaluate this variation. A *p-value* below the specified significance level of 0.05 was deemed statistically significant.

RESULTS

SOCIO-DEMOGRAPHIC CHARACTERISTICS OF THE PATIENT GROUP AND THE CONTROL GROUP

In the comparative study that dealt with the effect of specific variables between two groups, the results were as follows: Regarding age, the average age of the control group was 65.86 years with a standard deviation of 6.20, while the patient group recorded an average age of 62.27 years with a standard deviation of 6.48, and these differences did not show statistical significance. The P value was greater than 0.05. As for the body mass index (BMI), its average for the control group was 35.10 with a standard deviation of 6.77, compared to 36.28 with a standard deviation of 6.99 for the patient group. These results were also not statistically significant ($P > 0.05$). These data indicate that the difference in age and BMI between the two groups is not statistically significant in this research sample.

Table 1: Age and BMI among patients and control subjects

Parameters	Control group (n=35) Mean±SD	Patients group (n=35) Mean±SD	P. value
Age	65.86 ± 6.20	62.27 ± 6.48	>0.05 ^{NS}
BMI	35.10 ± 6.77	36.28 ± 6.99	>0.05 ^{NS}




Figure 1: Age and BMI among study group

DIFFERENCE IN LEVELS OF FASTING GLUCOSE, PROSTATE SENSITIVE ANTIGEN, AND LEPTIN BETWEEN PATIENTS AND THE CONTROL GROUP.

In analysing the results for the three variables included in the study, comparing the control group and the patient group, the following information is provided: The control group had a mean fasting glucose level (FBS) of 102.91 mg/dL, with a standard deviation of 9.30. Conversely, the group that was administered a dosage of 123.86 mg/dL exhibited a standard deviation of 17.66. In the patient group, this represented significant statistical significance ($P < 0.001$). As for the level of prostate-specific antigen (PSA), its average was 2.24 ng/ml with a standard deviation of 0.76 for the control group compared to 7.24 ng/ml with a standard deviation of 0.97 for the patient group, confirming statistical significance ($P < 0.001$). Finally, looking at leptin levels, a reading of 2.98 ng/ml with a standard deviation of 0.87 was recorded for the control group, compared to 6.63 ng/ml with a standard deviation of 1.18 for the patient group, with strong statistical significance ($P < 0.001$). These results show significant differences between the two groups in all three variables mentioned above.

Table 2: FBS, PSA and leptin levels among patients and control subjects

Parameters	Control group (n=35) Mean±SD	Patients group (n=35) Mean±SD	P. value
FBS	102.91 ± 9.30	123.86 ± 17.66	<0.001
PSA	2.24 ± 0.76	7.24 ± 0.97	<0.001
Leptin	2.98 ± 0.87	6.63 ± 1.18	<0.001




Figure 2: FBS, PSA and leptin levels among study group

DIFFERENCE IN LIPID LEVELS BETWEEN PATIENTS AND THE CONTROL GROUP.

The obtained data show statistically significant differences between the control group and the patient group regarding the levels of total cholesterol (T.C.) and triglycerides (TG). For total cholesterol levels, the average in the control group was 161.64 mg/dL with a standard deviation of 23.08; on the other hand, the patient group had a measured value of 212.05 mg/dL with a standard deviation of 17.33. This result indicates a statistically significant difference ($P < 0.001$). The control group had a mean triglyceride level of 154.00 mg/dL, with a standard deviation of 28.38. Conversely, the group of patients had an average of 179.05 mg/dL with a standard deviation of 19.95. These differences represent statistical significance ($P < 0.01$). These differences reflect important and significant changes between the two segments studied in the study.

Table 3: Total cholesterol and triglyceride levels among patients and control subjects

Parameters	Control group (n=35) Mean±SD	Patients group (n=35) Mean±SD	P. value
T.C	161.64 ± 23.08	212.05 ± 17.33	<0.001
TG	154.00 ± 28.38	179.05 ± 19.95	<0.01




Figure 3: Total cholesterol and triglyceride levels among study group

DIFFERENCE IN LIVER FUNCTION (GPT, GOT) LEVELS BETWEEN PATIENTS AND THE CONTROL GROUP.

Results regarding levels of the liver enzymes glutamic pyruvate transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) show that for the GPT enzyme, the mean in the control group is 13.59 U/L with a standard deviation of 3.59, while the mean in the patient group is 17.55 U/L with a standard deviation of 4.52. The differences between the two groups showed statistical significance ($P < 0.01$), which means that the increase in GPT levels for the patient group is considered statistically significant. For the GOT enzyme, the mean values in the control group were 19.45 U/L with a standard deviation of 6.55, while in the patient group it was 23.23 U/L with a standard deviation of 6.78. In this case, the statistical value (P value) was greater than 0.05 and was not marked as statistically significant (NS no significant), indicating that the observed differences were not statistically significant.

Table 4: Liver enzymes levels among patients and control subjects

Parameters	Control group (n=35) Mean±SD	Patients group (n=35) Mean±SD	P. value
GPT	13.59 ± 3.59	17.55 ± 4.52	<0.01
GOT	19.45 ± 6.55	23.23 ± 6.78	>0.05 ^{NS}




Figure 4: Liver enzymes levels among study group

THE DIFFERENCE IN LEVELS OF KIDNEY FUNCTION (UREA, CREATININE) BETWEEN PATIENTS AND THE CONTROL GROUP.

The levels of urea and creatinine in the blood, which are important indicators of kidney function, were analyzed. The control group had a mean value of 40.45 mg/dL for urea, with a standard deviation of 5.83. Conversely, the group of patients obtained an average measurement of 46.86 mg/dL, accompanied by a standard deviation of 6.84. This difference in urea level is statistically significant ($P < 0.01$). As for creatinine levels, they had an average of 0.74 mg/dL with a standard deviation of 0.19 for the control group, while the patient group presented a higher average of 0.99 mg/dL with a standard deviation of 0.18.

The difference here indicates very strong statistical significance ($P < 0.001$).

Table 5: Renal function test among patients and control subjects.

Parameters	Control group (n=35) Mean±SD	Patients group (n=35) Mean±SD	P. value
Urea	40.45 ± 5.83	46.86 ± 6.84	<0.01
Creatinine	0.74 ± 0.19	0.99 ± 0.18	<0.001




Figure 5: Renal function test among study group

PEARSON CORYLATION AMONG ALL BIOMARKERS INCLUDED IN THE STUDY.

The statistical relationships between the various variables in the study are shown through the Pearson correlation coefficient and the two-tailed indicative values (Sig. (2-tailed)). The results show that the body mass index (BMI) was not statistically significantly associated (.269) with the age of the participants ($P = .226$). The values indicate a statistically significant inverse relationship between the body mass index (BMI) and the prostate-specific antigen (PSA) level (-.429, $P = .046$), which indicates an increase in the PSA value with a decrease in BMI. Fasting blood sugar (FBS) and total cholesterol (TC) values were not statistically significantly related to age (.172 and .262, respectively), with P values of .444 and .239. There was a statistically significant positive correlation between triglyceride (TG) levels and total cholesterol (.452, $P = .035$). The relationship between the liver enzymes GPT and GOT and the rest of the variables did not show significant statistical significance. As for creatinine, a statistically significant inverse relationship with BMI appeared (-.470, $P = .027$), which means that the level of creatinine decreased with an increase in BMI. Urea also showed a statistically significant positive relationship with both age and fasting blood sugar (FBS) levels (.478 and .536, respectively), with P values of .024 and .010. It was found that there was a statistically significant inverse relationship between leptin and PSA (-.436, $P = .042$) and a significant positive relationship between leptin and CREA (.661, $P = .001$), while the relationship was stronger and inverse with GPT (-.555, $P = .007$).

Table 6: Correlation of study parameters with each other in patients group

Parameters		Age	BMI	PSA	FBS	TC	TG	GPT	GOT	CREA	UREA
BMI	Pearson Correlation	.269									
	Sig. (2-tailed)	.226									
PSA	Pearson Correlation	-.216	-.429*								
	Sig. (2-tailed)	.334	.046								
FBS	Pearson Correlation	.172	-.278	.328							
	Sig. (2-tailed)	.444	.211	.136							
TC	Pearson Correlation	.262	.182	-.458*	-.262						
	Sig. (2-tailed)	.239	.419	.032	.238						
TG	Pearson Correlation	-.023	.375	-.255	-.195	.452*					
	Sig. (2-tailed)	.918	.085	.253	.384	.035					
GPT	Pearson Correlation	.146	-.177	.160	-.147	.241	.354				
	Sig. (2-tailed)	.518	.430	.476	.514	.280	.106				
GOT	Pearson Correlation	.011	.026	.072	-.134	-.227	.112	.021			
	Sig. (2-tailed)	.960	.907	.751	.554	.309	.620	.928			
Creatinine	Pearson Correlation	.238	-.470*	.152	.385	-.066	-.151	.067	.064		
	Sig. (2-tailed)	.287	.027	.500	.077	.770	.504	.767	.776		
Urea	Pearson Correlation	.478*	-.085	.153	.536*	.033	.123	-.005	.021	.661**	
	Sig. (2-tailed)	.024	.708	.496	.010	.885	.586	.982	.927	.001	
Leptin	Pearson Correlation	-.343	.157	-.436*	-.238	.173	-.250	-.555**	-.232	-.149	-.226
	Sig. (2-tailed)	.119	.486	.042	.286	.442	.261	.007	.299	.508	.311

DISCUSSION

The given input is a list containing the elements (Hsing et al., 2007; Freedland et al., 2007). Multiple studies have investigated the association between leptin, body fatness, and prostate cancer. An association has been found between higher levels of leptin, specific prostatic antigen, and testosterone in patients with CaP compared to the control group and individuals with benign prostate hyperplasia (Saglam et al., 2003). Chang et al. discovered a positive connection between elevated leptin levels and the growth of bigger tumours. Empirical evidence suggests that the impact of leptin varies depending on the stages of CaP. Saglam et al. (Saglam et al., 2003) found a strong correlation between higher levels of leptin and a more advanced stage of the disease, as well as a poorly differentiated tumour. Leptin may impact the likelihood of clinically detectable CaP through factors associated with obesity (Hsing et al., 2007). The research conducted by Hsing et al. found that there is a correlation between leptin levels and the risk of developing CaP. However, it should be noted that this correlation is exclusively apparent in males whose waist-to-hip ratio exceeds 0.87. This finding implies that leptin might interact with biomarkers in adipose tissue, including sexual hormones or IGF-1, in order to elevate the probability of developing this particular form of cancer (Hsing et al., 2007). Theoretically, it is possible that increased amounts of leptin could impact the progression of

latent CaP to clinically detectable CaP. Studies conducted in controlled laboratory settings (in vitro) and on living beings (in vivo) have shown that this specific adipokine has the ability to induce angiogenesis, the biological process by which new blood vessels are created. This greatly enhances the growth and spread of various types of cancer, including CaP (Baillargeon et al., 2006; West DW et al., 1991). Furthermore, leptin has the capacity to increase levels of cytokines and growth factors, such as vascular epithelial growth factor (VEGF), a protein associated with the formation of cancer. Freedland et al. (Freedland et al., 2007), found that there is a positive correlation between high leptin concentrations and tumour volume. Saglam et al. (Saglam et al., 2003), have found that higher levels of leptin are linked to a more advanced stage of the disease and a tumour that is not well differentiated. Our study confirmed prior studies by showing that individuals with advanced-stage cancer had higher levels of leptin and BMI compared to those with less advanced-stage cancer (Freedland et al., 2007; Saglam et al., 2003). Males observe a significant increase in blood leptin levels shortly before or during early puberty, which thereafter decrease to normal levels when testosterone levels rise. Leptin may influence the timing of gland reactivation that occurs just before the increase in testosterone. Prostate cancer (PCa) showed a significantly higher proportion of leptin expression compared to benign prostatic hyperplasia (BPh) and healthy prostatic tissue. Thus, prostate cancer cells can ex-

AUTHORS CONTRIBUTION

Nesreen Ahmed Nasser conceived the study, designed the methodology, and analyzed the data. Anas H. Sadek conducted data collection and statistical analysis, and drafted the manuscript. Bayader Abdul Hussan Muhameed assisted with data collection and manuscript preparation. Osama Akram Mohsein oversaw the project, provided guidance, and coordinated the research and writing process.

REFERENCES

- Ang WH, Chen JC, Hsu KH, Lin CY, Wang SW, Wang SJ, Chang YS, Tang CH (2014). Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. *Biochim. Biophys. Acta*, 1840: 3483–3493. <https://doi.org/10.1016/j.bbagen.2014.09.012>
- Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al (2006). Obesity, adipokines, and prostate cancer in a prospective population based study. *Cancer Epidemiol Biomarkers Prev.*, 15:1331–5. <https://doi.org/10.1158/1055-9965.EPI-06-0082>
- Brawer MK (2003). Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. *Rev. Urol.* 5(Suppl 1):S29–33.
- Charchour R, Dufour-Rainfray D, Morineau G, Vatie C, Fellahi S, Vigouroux C, Genoux A, Capeau J, Lacorte JM; Collet C et al (2020). Multifaceted biological roles of leptin. *Ann. Biol. Clin.* 78: 231–242 <https://doi.org/10.1684/abc.2020.1560>
- Considine RV, Sinha MK, Heimann ML et al (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl. J. Med.*, 334:292–5. <https://doi.org/10.1056/NEJM199602013340503>
- Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. *Epidemiol. Rev.* 29:88–97. <https://doi.org/10.1093/epirev/mxm006>
- Garcia-Castano A, Madariaga L, de Nancrales GP, Ariceta G, Gaztambide S, Castano L (2019). Novel mutations associated with inherited human calcium-sensing receptor disorders: A clinical genetic study. *Eur. J. Endocrinol.* 180: 59–70. <https://doi.org/10.1530/EJE-18-0129>
- Gorab A, Pagano A, Ayed K, Chebil M, Derouiche A, Kovacic H, Gati A (2020). Leptin Promotes Prostate Cancer Proliferation and Migration by Stimulating STAT3 Pathway. *Nutr. Cancer.* 10: 1–11. <https://doi.org/10.1080/01635581.2020.1792946>
- Hoon Kim J, Lee Sy, Myung SC, et al. (2008). Clinical significance of the leptin and leptin receptor expressions in prostate tissues, *Asian J. Androl.*, 10:923–8 <https://doi.org/10.1111/j.1745-7262.2008.00438.x>
- Hsing AW, Sakoda LC, Chua S Jr (2007). Obesity, metabolic syndrome, and prostate cancer. *Am. J. Clin. Nutr.* 86:s843–57. <https://doi.org/10.1093/ajcn/86.3.843S>
- Lateef D, Nasser N, Mohsein O (2024). The relationships between Aplein, Vaspain and thyroid hormone levels in obese diabetic and non-diabetic women. *J. Exper. Clin. Med.*, 41(2): 239–245.
- Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, Sánchez-Margalet V (2020). Role of leptin in inflammation and vice versa. *Int. J. Mol. Sci.* 21: 5887. <https://doi.org/10.3390/>

exploit the leptin receptor, which is normally found on prostatic epithelial cells, to promote their growth in obese men who have consistently elevated levels of leptin (hoon et al., 2008). There is a suggested link between the levels of leptin in the blood and both body mass index (BMI) and the amount of fat in the body in healthy males. This connection may explain why there is a relationship between prostate cancer (PCa) and obesity. The observed positive connection can be explained by the greater leptin secretion from larger adipocytes compared to smaller adipocytes. Obese individuals emit about eight times more leptin per fat cell compared to thin subjects (Considine et al., 1996).

CONCLUSION

Excessive fat tissue in the body and high levels of leptin in the blood are linked to the aggressiveness of prostate cancer, rather than being variables that increase the risk of developing the disease.

ETHICAL CONSIDERATIONS

Each parent or guardian of the patients who took part in the trial provided a written consent form. The current investigation was carried out in accordance with the ethical principles specified in the Declaration of Helsinki (1964) for medical studies involving human subjects. The research and ethical committee of the Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq, approved the request.

ACKNOWLEDGEMENTS

Thanks and gratitude to all contributors to the research and to the Department of Clinical Chemistry at the College of Medicine, Al-Nahrain University, and to the professors who offered assistance in completing the research project.

CONFLICT OF INTEREST

We declare that there is no conflict of interest between all researchers.

NOVELTY STATEMENT

This study investigates the novel relationship between prostate-specific antigen (PSA) and leptin hormone levels in prostate cancer patients. While PSA is a well-known biomarker, the role of leptin in this context is underexplored. This research aims to uncover potential correlations between these markers, potentially enhancing diagnostic and prognostic insights into prostate cancer.

ijms21165887

- Saglam D, Aydur E, Yilmaz I, Goktas S (2003). Leptin influences cellular differentiation and progression in prostate cancer. *J. Urol.* 169:1308-11. <https://doi.org/10.1097/01.ju.0000055903.18400.25>
- West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991). Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. *Cancer Causes Control.* 2: 85-94 <https://doi.org/10.1007/BF00053126>
- Xu CJ, Dong LL, Kang XL, Li ZM, Zhang HY (2020). Leptin promotes proliferation and inhibits apoptosis of prostate cancer cells by regulating ERK1/2 signaling pathway. *Eur. Rev. Med. Pharmacol. Sci.* 24; 8341-8348.
- Yang WH, Chang AC, Wang SW, Wang SJ, Chang YS, Chang TM, Hsu SK, Fong YC, Tang CH (2016). Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. *Sci. Rep.*, 6: 28647 <https://doi.org/10.1038/srep28647>
- Zhang Y, Chua S Jr (2017). Leptin Function and Regulation. *Compr. Physiol.* 8: 351-369. <https://doi.org/10.1002/cphy.c160041>
- Zhang Y, Liu L, Li C, Ai H (2014). Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer. *Cancer Biomark. Sect. A Dis. Markers.* 14: 353-359. <https://doi.org/10.3233/CBM-140415>
- Zou H, Liu Y, Wei D, Wang T, Wang K, Huang S, Liu L, Li Y, Ge J, Li X et al (2016). Leptin promotes proliferation and metastasis of human gallbladder cancer through OB-Rb leptin receptor. *Int. J. Oncol.* 49: 197-206. <https://doi.org/10.3892/ijo.2016.3530>